Skip to main content

Meridian Bioscience Simplifies COVID-19 Sample Prep and Eliminates Dependence on Reagents in Short Supply

Written by Customer Service on . Posted in Public Companies.

CINCINNATI, April 27, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today the launch of a novel enzyme master mix (Inhibitor Tolerant 1-step RT-qPCR Mix) that eliminates the need to use an RNA extraction kit prior to running the patient sample through a molecular assay.  By eliminating this step, total assay cost is lower and processing times for COVID-19 samples can be reduced by as much as 30 minutes per test. 
To date, most COVID-19 molecular assays require laboratories to first isolate and purify the SARS-CoV-2 viral RNA from a patient sample (saliva or nasopharyngeal).  This step is not only complex and time consuming, but also adds to the overall cost of the COVID-19 assay.  In addition, RNA sample extraction kits have not been readily available during this pandemic.  To address these shortfalls, scientists at Meridian have successfully developed a proprietary master mix formulation, which when combined with SARS-CoV-2 primers and probes, will enable laboratories to eliminate the SARS-CoV-2 viral RNA purification step.  Patient samples will not require complex processing before running the test when using this master mix in the assay.  This innovative advancement in master mix formulation has applications not only in today’s COVID-19 assays, but the future of molecular assays as well.“This new master mix is a paradigm shift in how laboratories will process biological samples for molecular testing,” said Todd Howren, Ph.D., Vice President of Global Sales for Meridian Life Science, in a statement earlier today.  “We have already shared this new master mix with nearly 20 early access laboratories around the globe, and their feedback has been quite positive.  We are now ready to launch this innovative product to the broader market in hopes of addressing the bottlenecks faced by many labs.  To that end, we are looking to align with developers and manufactures of COVID-19 molecular assays in order to quickly bring this novel solution to bear in the fight against COVID-19.”Meridian is committed to suppling innovative solutions to the diagnostic industry during times of a pandemic health crisis. For more information on partnering with Meridian Bioscience please visit meridianlifescience.com or contact: todd.howren@meridianbioscience.com.About Meridian Bioscience, Inc.Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing.  We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.Contact:
Charlie Wood
Vice President – Investor Relations Meridian Bioscience, Inc.
Phone:  +1 513.271.3700
Email: mbi@meridianbioscience.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.